Insulin degludec: Pharmacokinetic properties in subjects with hepatic impairment

Clinical Drug Investigation

Volumn 34, Issue 2, 2014, Pages 127-133

  Kupčová, Viera ^a   Arold, Gerhard ^b   Roepstorff, Carsten ^c   Højbjerre, Malene ^c   Klim, Søren ^c   Haahr, Hanne ^c  

^a UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^b PRA International   (Germany)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DEGLUDEC; ORAL ANTIDIABETIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; HYPOGLYCEMIA; LIVER FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MILD HEPATIC IMPAIRMENT; MODERATE HEPATIC IMPAIRMENT; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEVERE HEPATIC IMPAIRMENT; STEADY STATE; URINALYSIS; YOUNG ADULT;

ADULT; AREA UNDER CURVE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN, LONG-ACTING; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84899030576     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0154-1     Document Type: Article

References (25)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;5:1577-96.
2. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673-9. (Pubitemid 43951158)
3. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab. 2012. doi:10.1111/j.1463-1326. 2012.01636.x.
4. Donnelly LA, Morris AD, Evans JM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100:345-50. (Pubitemid 47073810)
5. Molyneaux LM, Constantino MI, McGill M, et al. Better glycaemic control and risk reduction of diabetic complications in type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract. 1998;42:77-83. (Pubitemid 28558945)
6. Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia. 2011;54:S426.
7. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;9:2104-14.
8. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859-64.
9. Heise T, Nosek L, Bøttcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944-50.
10. Meneghini LF, Atkin SL, Gough SCL, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36:858-64.
11. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175-84.
12. Morello CM. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus. Int J Gen Med. 2011;4:827-35.
13. Quintana JO, García-Compean D, González JA, et al. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. Ann Hepatol. 2011;10:56-62.
14. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30:734-43. (Pubitemid 46354365)
15. European Medicines Agency. Sanofi. Lantus® EPAR. October 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/ human/000284/WC500036082.pdf. Accessed 28 Jun 2013.
16. European Medicines Agency. Novo Nordisk A/S. Levemir® EPAR. October 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product- Information/human/000528/WC500036662.pdf. Accessed 28 Jun 2013.
17. Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol. 2005;60:469-76. (Pubitemid 41532446)
18. European Medicines Agency. Eli Lilly and Company. Humalog® EPAR. October 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Product-Information/human/000088/WC500050332.pdf. Accessed 28 Jun 2013.
19. Ryysy L, Häkkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes. 2000;49:749-58. (Pubitemid 30339990)
20. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-9.
21. U.S. Department of Health and Human Services & Food and Drug Administration. Guidance for Industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis and impact on dosing and labeling. 2003. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf. Accessed 26 Jun 2013.
22. European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. CPMP/EWP/2339/02. http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003122.pdf. Accessed Jan 2012.
23. American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes. Diabetes Care. 2005;28:1245-9.
24. Kiss I, Arold G, Roepstorff C, et al. Insulin degludec: Pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2013. doi:10.1007/s40262-013-0113-2.
25. Narita R, Abe S, Kihara Y, et al. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol. 2004;41:132-8. (Pubitemid 39005164)